19 January 2023 - - Jonathan Talamo, MD has been appointed as the new chair of US-based clinical-stage company CXL Ophthalmics, Inc's board of directors, the company said.

Dr. Talamo has served as a Board Member for the company since 2020.

Dr. Talamo, an ophthalmic surgeon with over 25 years in clinical practice, is in corneal disease, cataract, and refractive surgery.

After 25 years in the clinic, he pivoted to executive roles in biomedicine and healthcare.

As Chief Medical officer of Ocular Therapeutix, Dr. Talamo helped usher the development of Dextenza for post-surgical inflammation and managed a pipeline of ophthalmologic therapeutics.

In his subsequent role as Chief Medical officer and Worldwide vice president of Clinical and Medical Affairs at Johnson & Johnson Vision, Dr. Talamo helped lead the integration of Abbott Medical Optics and the global launch of multiple ophthalmologic products.

CXLO is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally.

Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.